{"filing":{"accession_number":"0001664710-26-000053","cik":"0001664710","ticker":"KROS","company_name":"Keros Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"kros-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/kros-20260908.htm"},"events":[{"id":31943,"run_id":29339,"accession_number":"0001664710-26-000053","anchor_item_number":"8.01","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Company announced a board-approved $5 million share repurchase program, which constitutes a return of capital to shareholders. Although the Item 8.01 disclosure also mentions receipt of a $20 million development milestone payment from Takeda, the principal disclosed action is the authorization and announcement of the repurchase program. Share repurchases are classified as dividend_distribution events under the taxonomy as they represent distributions or returns of capital to holders.","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34984,"accession_number":"0001664710-26-000053","item_number":"8.01","item_title":"Other Events.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company announced a board-approved $5 million share repurchase program, which constitutes a return of capital to shareholders. Although the Item 8.01 disclosure also mentions receipt of a $20 million development milestone payment from Takeda, the principal disclosed action is the authorization and announcement of the repurchase program. Share repurchases are classified as dividend_distribution events under the taxonomy as they represent distributions or returns of capital to holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:05:07.488907+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34984,"accession_number":"0001664710-26-000053","item_number":"8.01","item_title":"Other Events.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company announced a board-approved $5 million share repurchase program, which constitutes a return of capital to shareholders. Although the Item 8.01 disclosure also mentions receipt of a $20 million development milestone payment from Takeda, the principal disclosed action is the authorization and announcement of the repurchase program. Share repurchases are classified as dividend_distribution events under the taxonomy as they represent distributions or returns of capital to holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:05:07.488907+00:00","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-09-08"}]}